Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This study focuses on artificial intelligence-driven classification of glioma and Ki-67 leveling using T2w-FLAIR MRI, exploring the association of Ki-67 biomarkers with deep learning (DL) features through explainable artificial intelligence (XAI) and SHapley Additive exPlanations (SHAP). This IRB-approved study included 101 patients with glioma brain tumor acquired MR images with the T2W-FLAIR sequence. We extracted DL bottleneck features using ResNet50 from glioma MR images. Principal component analysis (PCA) was deployed for dimensionality reduction. XAI was used to identify potential features. The XGBosst classified the histologic grades of the glioma and the level of Ki-67. We integrated potential DL features with patient demographics (age and sex) and Ki-67 biomarkers, utilizing SHAP to determine the model's essential features and interactions. Glioma grade classification and Ki-67 level predictions achieved overall accuracies of 0.94 and 0.91, respectively. It achieved precision scores of 0.92, 0.94, and 0.96 for glioma grades 2, 3, and 4, and 0.88, 0.94, and 0.97 for Ki-67 levels (low: 5%≤Ki-67<10%, moderate: 10%≤Ki-67≤20, and high: Ki-67>20%). Corresponding F1-scores were 0.95, 0.88, and 0.96 for glioma grades and 0.92, 0.93, and 0.87 for Ki-67 levels. SHAP analysis further highlighted a strong association between bottleneck DL features and Ki-67 biomarkers, demonstrating their potential to differentiate glioma grades and Ki-67 levels while offering valuable insights into glioma aggressiveness. This study demonstrates the precise classification of glioma grades and the prediction of Ki-67 levels to underscore the potential of AI-driven MRI analysis to enhance clinical decision-making in glioma management.

Original publication

DOI

10.1016/j.compmedimag.2025.102578

Type

Journal article

Journal

Comput Med Imaging Graph

Publication Date

09/2025

Volume

124

Keywords

Dimensionality reduction, Explainable artificial intelligence, Glioma classification, Ki-67 biomarkers, Ki-67 level prediction, Machine learning, Pre-trained deep learning, Shapley Additive Explanations, Humans, Glioma, Ki-67 Antigen, Magnetic Resonance Imaging, Neoplasm Grading, Brain Neoplasms, Male, Female, Middle Aged, Adult, Deep Learning, Image Interpretation, Computer-Assisted, Aged, Biomarkers, Tumor, Artificial Intelligence